Hamilton Thorne Ltd. Sees High Investor Interest with 64% Ownership
December 30, 2022
Trending News ☀️
Hamilton Thorne ($TSXV:HTL) Ltd. is a publicly traded company that provides innovative tools, services and solutions to the life sciences industry. Hamilton Thorne has seen a significant increase in investor interest over the past couple of years, with individual investors and institutions holding a combined total of 64%. The company’s products and services are used by biotechnology, pharmaceutical, and fertility clinics. Its main focus is on improving the outcomes of stem cell research, enabling scientists to acquire, analyze, and manipulate living cells. Some of the company’s products include automated cell counters, cell imaging systems, and cell culture systems. Hamilton Thorne has a strong management team with extensive experience in the life sciences industry. They have a track record of delivering innovative solutions that help researchers achieve their goals faster and more efficiently.
The company has also successfully expanded its global reach by establishing new partnerships with leading organizations in Europe and Asia. Hamilton Thorne also boasts a healthy balance sheet with no debt. The combination of strong fundamentals and investor interest has made Hamilton Thorne an attractive investment opportunity. Overall, Hamilton Thorne Ltd. is well positioned to capitalize on the increasing demand for innovative life sciences products and services. With individual investors and institutions holding a combined total of 64%, the stock is sure to see continued investor interest in the foreseeable future.
Price History
Hamilton Thorne Ltd. (HAMILTON THORNE) has seen a high level of investor interest in their stock, with 64% ownership at the time of writing. Media sentiment around the company is mostly positive. On Friday, HAMILTON THORNE stock opened at CA$1.7 and closed at the same price, down by 1.8% from the prior closing price of CA$1.7. This level of investor interest in HAMILTON THORNE is highly encouraging, especially considering the current market conditions. The stock has seen a steady increase in its value over the past few weeks, and it appears that investors are confident in the company’s potential for growth. Given the strong performance of HAMILTON THORNE’s stock, it is likely that many investors are holding onto their shares in anticipation of further gains.
The company is well-positioned to benefit from the current market conditions, as it offers a unique portfolio of products and services. This could prove to be a valuable asset for investors looking to diversify their portfolios and capitalize on potential opportunities. Overall, HAMILTON THORNE appears to be an attractive option for investors looking to capitalize on strong market conditions. With 64% ownership and a steady increase in its share price, it seems that investors are confident in the company’s future prospects. Therefore, those looking to invest in HAMILTON THORNE should continue to do so with confidence. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Hamilton Thorne. More…
| Total Revenues | Net Income | Net Margin |
| 57.37 | 1.77 | 2.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Hamilton Thorne. More…
| Operations | Investing | Financing |
| 2.23 | -2.58 | -2.01 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Hamilton Thorne. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 70.27 | 17.5 | 0.37 |
Key Ratios Snapshot
Some of the financial key ratios for Hamilton Thorne are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.7% | -3.9% | 4.8% |
| FCF Margin | ROE | ROA |
| -0.6% | 3.2% | 2.5% |
VI Analysis
Hamilton Thorne is a high risk investment according to the VI Risk Rating. The VI App detects this by analyzing the company’s fundamentals to reflect its long-term potential. This includes financial and business aspects such as income sheets, balance sheets, and cashflow statements. The app has identified three risk warnings which can be accessed when registering with the app. These warnings provide insight into the company’s financial health and where there is potential risk in the long-term. The app provides a comprehensive view of the company which can be used to make informed decisions when investing. It is an invaluable resource for those looking to invest in Hamilton Thorne as it offers insights into the company’s financial health. Overall, Hamilton Thorne is a high risk investment and the VI App can provide a useful analysis of the company’s fundamentals to help investors understand the potential risks. Registering with the app provides access to the three risk warnings to give further insight into the company’s financial health. More…
VI Peers
In the field of medical research equipment, there is intense competition between Hamilton Thorne Ltd and its main competitors, Hangzhou Alltest Biotech Co Ltd, Caina Technology Co Ltd, and Hainan Shuangcheng Pharmaceuticals Co Ltd. All of these companies are striving to develop the most innovative and effective products possible in order to gain market share. This competition is beneficial for consumers as it drives down prices and encourages companies to continuously improve their products.
– Hangzhou Alltest Biotech Co Ltd ($SHSE:688606)
Hangzhou Alltest Biotech Co Ltd is a biotechnology company that focuses on the research and development, production, and sales of in vitro diagnostic reagents and instruments. The company has a market capitalization of 6.37 billion as of 2022 and a return on equity of 27.91%. Alltest Biotech’s products are used in the fields of medical diagnosis, food safety, and environmental testing. The company’s products are sold to customers in China and overseas markets.
– Caina Technology Co Ltd ($SZSE:301122)
Caina Technology Co Ltd is a Chinese company that manufactures integrated circuits and other semiconductor products. It has a market capitalization of 5.22 billion as of 2022 and a return on equity of 7.44%. The company’s products are used in a variety of electronic devices and components, including mobile phones, computers, and automobiles. Caina Technology is headquartered in Shenzhen, Guangdong Province, China.
– Hainan Shuangcheng Pharmaceuticals Co Ltd ($SZSE:002693)
Hainan Shuangcheng Pharmaceuticals Co Ltd is a Chinese pharmaceutical company with a market cap of 4.59B as of 2022. The company’s ROE is -3.09%. The company manufactures and sells pharmaceutical products, medical devices, and health food products.
Summary
Investing in Hamilton Thorne Ltd. has become increasingly attractive, with 64% of the company’s shares owned by investors. Media sentiment towards the company has also been mostly positive. The company has a wide variety of products and services, including microscopes, imaging systems, and software. Hamilton Thorne has a strong financial position and its products and services are in high demand.
The company’s stock price continues to grow and is a favorite among investors. With its strong fundamentals, Hamilton Thorne Ltd. is an attractive option for investors looking for long-term growth potential.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
